ias 2011, rome, july 17 - 20

14
Generic protocol for national population-based impact evaluation of national programs for PMTCT at 6 weeks post-partum Thu-Ha Dinh, MD., MS., US CDC/GAP IAS 2011, Rome, July 17 - 20

Upload: sian

Post on 21-Feb-2016

43 views

Category:

Documents


0 download

DESCRIPTION

Generic protocol for national population-based impact evaluation of national programs for PMTCT at 6 weeks post-partum Thu-Ha Dinh, MD., MS., US CDC/GAP. IAS 2011, Rome, July 17 - 20. Overview of Presentation. Background -- Justification of the evaluation Evaluation questions - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: IAS 2011, Rome,  July 17 - 20

Generic protocol for national population-based impact evaluation of national programs for

PMTCT at 6 weeks post-partum

Thu-Ha Dinh, MD., MS., US CDC/GAP

IAS 2011, Rome, July 17 - 20

Page 2: IAS 2011, Rome,  July 17 - 20

Overview of Presentation• Background -- Justification of the evaluation• Evaluation questions • Primary objectives• Who – Where – How• Ethical consideration• Methods

• Design• Sample size• Testing algorithms

• Procedure• Data management – storage – analysis• Dissemination of findings

Page 3: IAS 2011, Rome,  July 17 - 20

PMTCT effectiveness• HIV transmission – proximate purpose of

programs is to reduce MTCT of HIV• ARV prophylaxis • Safe feeding• Maternal ART

• HIV free survival – ultimate goal of programs is to save children from HIV & death

• Time points: – Perinatal and during breast-feeding (6 wks, 6

months, 9 months, 12 months, 18 months, etc)

Page 4: IAS 2011, Rome,  July 17 - 20

Why do we need national population estimate?

• Overall effectiveness of the program• Assess mother-infant pairs in PMTCT and not

reached • Provide unbiased estimate of HIV-infected

infants/children

Page 5: IAS 2011, Rome,  July 17 - 20

Primary Evaluation Question• What is population-based perinatal MTCT rate measured

at 6 weeks? What is the HIV exposure prevalence among infants at 6 weeks ? What is the HIV infection prevalence among infants, 6 weeks What is the coverage of each PMTCT service along PMTCT cascade?

Page 6: IAS 2011, Rome,  July 17 - 20

How we measure HIV exposure prevalence?• Self-reported HIV positive status from mother?

– Self-report bias– HCT uptake

• Documented HIV positive status of mother during pregnancy?– Information documented – HCT uptake

• Identify maternal HIV antibody in targeted infant (biomedical marker) ? – No bias: self-report or HCT uptake or information doc.– Include HIV acquisition– Sensitivity and specificity of the antibody test used

Page 7: IAS 2011, Rome,  July 17 - 20

0-1 m 1-2 m 2-6 m 6-9 m 9-12 m 12-18 m

Maternal HIV ABHIV DNAinf_HIV Ab

Blood sample of HIV-infected in-fant

Thanks to Elaine Abrams and Nigel Rollinsx

Identify maternal HIV antibody in Infant

HIV

Ab

test

Thanks to E. Abram and N. Rollins

Page 8: IAS 2011, Rome,  July 17 - 20

Where we can recruit representative sample of the infant population?

• At labor and delivery clinic?– Home delivery?– HCT during ANC, L&D

• At home – household survey?• HCT during ANC, L&D– Not part of routine - expensive

• At immunization clinic?– The 1st immunization coverage >80%– The 1st immunization coverage 70% - 80% special

sample size and sub-study will be required to adjust for findings

Page 9: IAS 2011, Rome,  July 17 - 20

Design an Evaluation

• Questions objectives variables needed• Who: inclusion and exclusion, age range (4-8, 6-8?)• Where: to recruit potential participants • Ethical consideration• Design

– Cross-sectional design point estimate (6 weeks)– Sampling frame:

• multistage (province, facility) select facilities• participants from each selected facility (potential participant

load systematic or random or consecutive)

Page 10: IAS 2011, Rome,  July 17 - 20

Design: Sample size

• Estimate HIV prevalence in pregnant women• Estimate ARV uptake among HIV+ pregnant women• Estimate/collect existing MTCT • Specify the appropriate level of precision• Assume a design effect of 2 and double the

calculated sample size to take account of cluster sampling

Page 11: IAS 2011, Rome,  July 17 - 20

Design: Procedure

Eligible caregiver-infants

Do consent to take part in the survey

Don't consent to take part in the survey

Caregiver interview and infant-DBS

Caregiver interview and no infant-DBS

HIV DNA PCR positive(HIV-infected infant)

HIV DNA PCR negative (HIV uninfected infant)

HIV Ab Negative(HIV-unexposed infant)

HIV Ab positive(HIV-exposed infant)

Standard of care recommended

by WHO

Page 12: IAS 2011, Rome,  July 17 - 20

Consent and interview processcaregivers vs. mothers

Decision needs to be based on• Local situation all legal caregivers

– Orphan population – Proportion of mothers who work– Local child Act toward health care right/assess – Community consent acceptable ?

• Precision needed for estimate• Infant benefit vs. Mother benefit• Who should receive test result? ? validity of findings if caregivers excluded

Page 13: IAS 2011, Rome,  July 17 - 20

Design: Data management/Storage/Analysis • Data management:

– Quality control: at facility and at survey office– Data entry and safety– Who can access to the data – Ownership of the data

• Storage:– Paper-based: when paper-based will be destroyed– Public domain: how and when

• Data analysis– Dummy tables key outcomes – Identify potential bias can be controlled by analysis

collect those variables

Page 14: IAS 2011, Rome,  July 17 - 20

Dissemination of findings

• Provide feedback to clinics and provinces to improve/scale up program

• Provide feedback to provincial DOH and national MOH

• Share findings and lessons learned with other donors and organizations

• Publish findings on peer review journals